Find clinical trials | Bayside Health (Alfred)

DEFiNE GPS

Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting (short title: DEFiNE GPS) (NCT04451044)

Currently recruiting

DEFINER X50

DEFINERx050: A Multicentre, Randomized, Open-Label Study of Atezolizumab [Anti-PD-L1 Antibody] Plus Bevacizumab [Anti-VEGF Antibody] as Neo-Adjuvant therapy Versus Active Surveillance in Hepatocellular Carcinoma Patients with High Onco-Fetal Characteristics Before Surgical Resection (ACTRN12624001345572)

Evaluate the efficacy and safety of neoadjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance prior to surgical resection in early-stage HCC patients who are at high risk for disease recurrence.

Currently recruiting

DeLLphi-304

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (NCT05740566)

No longer recruiting

DeLLphi-308

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeLLphi-308] (NCT06598306)

Currently recruiting

DeLLphi-308

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeLLphi-308] (NCT06598306)

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Currently recruiting

DepleTTR-CM

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (NCT06183931)

No longer recruiting

Dianthus-CAPTIVATE

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) (NCT06858579)

The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).

Currently recruiting

DIRECT Trial

GuiDIng energy provision using indiREct CalorimeTry: a pilot feasibility randomised controlled trial in critically ill adults with obesity [DIRECT Trial] (NCT06053216)

Indirect calorimetry is the gold standard for measuring energy expenditure in critically ill patients, but its impact on outcomes versus predictive equations is unclear. This study assesses the feasibility of using repeated measurements to guide energy delivery in obese ICU patients, with a secondary goal of informing a larger trial.

Currently recruiting

Discovery 530 cardiac camera LVEF study

Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (Trial Not Registered)

Currently recruiting

DISCUS

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)

Currently recruiting

DREAMM-10

A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone [BRd] versus daratumumab, lenalidomide, and dexamethasone [DRd] in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (NCT06679101)

The study will evaluate if belantamab mafodotin, lenalidomide and dexamethasone prolongs progression-free overall survival compared to daratumumab, lenalidomide and dexamethasone in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

Currently recruiting

DREAMM7

DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma – DREAMM 7 (NCT04246047)

Currently recruiting

Dren Bio DR-0201-AIM-001

A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients with Select Autoimmune Rheumatic Diseases (NCT06647069)

The DR-0201-AIM-001 study is designed to evaluate the safety and efficacy of DR-0201 in adult participants with lupus, primary Sjögren’s syndrome and/or scleroderma.
Participants receive trial medication via an infusion over 26 weeks at varying intervals.

Currently recruiting

DRESS

Assessing the role of mepolizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome: a pilot study (ACTRN12621001333808)

No longer recruiting

DRI19220

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa [BRIGHTEN] (NCT07170917)

The purpose of this study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe Hidradenitis Suppurativa (HS). Participants will be in the study for up to 60 weeks and have the option to enter a long-term extension study for an additional 52 weeks. The treatment will be administered via subcutaneous injection (small injection into the abdomen) every two weeks.

Currently recruiting

DROP-FPF

A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (NCT07201922)

A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening.

Currently recruiting

DSP107_003

A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination with Atezolizumab Versus Fruquintinib in Patients with Advanced Microsatellite Stable Colorectal Cancer (NCT07235293)

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Currently recruiting

DUET-UC

A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis (NCT05242484)

Currently recruiting

DURGA-4 D8311C00001

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell [CAR-T] Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (NCT07391657)

A Phase III, Open-label, Randomised, Multicentre Study Comparing AZD0120 (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma.

Coming soon

DZ2022B0002

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (NCT05824585)

Currently recruiting